Interview with Bruna B. Rocha – In Vivo Citeline Commercial
Nations in Latin America and the Caribbean have officially initiated discussions on establishing a new regulatory body for medicines and medical devices in the region. This endeavor holds the promise of advantages for both companies and patients, such as alleviating regulatory complexities, facilitating market access, and enhancing the safety, quality, and efficacy of products.
In an interview with In Vivo Citeline Commercial, Bruna B. Rocha, our Life Sciences, Healthcare, and Cannabis partner, discussed the country’s potential involvement in this regulatory body and explored key influencing factors.
